The University of Chicago Header Logo

Connection

Wendy Stock to Humans

Back to Details
This is a "connection" page, showing publications Wendy Stock has written about Humans.
Wendy Stock
Connection Strength
2.178
Humans
  1. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.031
  2. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
    View in: PubMed
    Score: 0.029
  3. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092.
    View in: PubMed
    Score: 0.027
  4. Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered! JCO Oncol Pract. 2022 07; 18(7):479-487.
    View in: PubMed
    Score: 0.027
  5. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022 Mar; 101(3):557-569.
    View in: PubMed
    Score: 0.026
  6. OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.
    View in: PubMed
    Score: 0.025
  7. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 06; 11(6):1440-1453.
    View in: PubMed
    Score: 0.025
  8. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512.
    View in: PubMed
    Score: 0.025
  9. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913.
    View in: PubMed
    Score: 0.024
  10. Thrombosis in ALL: a risk without clear mitigation. Blood. 2020 07 16; 136(3):264-265.
    View in: PubMed
    Score: 0.024
  11. Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57.
    View in: PubMed
    Score: 0.024
  12. Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. JCO Oncol Pract. 2020 05; 16(5):231-238.
    View in: PubMed
    Score: 0.023
  13. Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL. Blood. 2019 04 18; 133(16):1715-1719.
    View in: PubMed
    Score: 0.022
  14. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559.
    View in: PubMed
    Score: 0.021
  15. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 01 08; 3(1):96-104.
    View in: PubMed
    Score: 0.021
  16. Should immunologic strategies be incorporated into frontline ALL therapy? Best Pract Res Clin Haematol. 2018 12; 31(4):367-372.
    View in: PubMed
    Score: 0.021
  17. Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole. Antimicrob Agents Chemother. 2018 07; 62(7).
    View in: PubMed
    Score: 0.021
  18. "Dar"-ing to target CD38 in T-ALL. Blood. 2018 03 01; 131(9):948-949.
    View in: PubMed
    Score: 0.020
  19. Management of acute lymphoblastic leukemia in young adults. Clin Adv Hematol Oncol. 2018 Feb; 16(2):138-146.
    View in: PubMed
    Score: 0.020
  20. Progress in adult ALL: incorporation of new agents to frontline treatment. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):28-36.
    View in: PubMed
    Score: 0.020
  21. Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML. Oncology (Williston Park). 2017 Mar 15; 31(3):190, 192.
    View in: PubMed
    Score: 0.019
  22. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
    View in: PubMed
    Score: 0.019
  23. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395.
    View in: PubMed
    Score: 0.018
  24. The Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What? Biol Blood Marrow Transplant. 2016 11; 22(11):1913-1914.
    View in: PubMed
    Score: 0.018
  25. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017 06; 17(3):274-279.
    View in: PubMed
    Score: 0.018
  26. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306.
    View in: PubMed
    Score: 0.018
  27. Novel drug targets in acute leukemia. Clin Adv Hematol Oncol. 2015 Aug; 13(8):493-5.
    View in: PubMed
    Score: 0.017
  28. Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia? Leuk Lymphoma. 2015; 56(11):3005-7.
    View in: PubMed
    Score: 0.017
  29. How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood. 2015 Jun 11; 125(24):3702-10.
    View in: PubMed
    Score: 0.016
  30. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
    View in: PubMed
    Score: 0.016
  31. RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Apr; 56(4):1145-7.
    View in: PubMed
    Score: 0.016
  32. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43.
    View in: PubMed
    Score: 0.015
  33. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.
    View in: PubMed
    Score: 0.014
  34. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.013
  35. Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma. 2012 Aug; 53(8):1543-51.
    View in: PubMed
    Score: 0.013
  36. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012 Apr; 97(4):579-85.
    View in: PubMed
    Score: 0.013
  37. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53.
    View in: PubMed
    Score: 0.013
  38. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
    View in: PubMed
    Score: 0.013
  39. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec; 45(12):1692-8.
    View in: PubMed
    Score: 0.012
  40. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2010 Feb; 51(2):188-98.
    View in: PubMed
    Score: 0.012
  41. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat. 2010 Jan; 119(2):391-8.
    View in: PubMed
    Score: 0.011
  42. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:21-9.
    View in: PubMed
    Score: 0.011
  43. Preface: acute lymphoblastic leukemia--quo vadis? Hematol Oncol Clin North Am. 2009 Oct; 23(5):xi-xviii.
    View in: PubMed
    Score: 0.011
  44. Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct; 23(5):1099-119, vii.
    View in: PubMed
    Score: 0.011
  45. Clinical trials in adult AML. Clin Adv Hematol Oncol. 2009 Jun; 7(6):8-10.
    View in: PubMed
    Score: 0.011
  46. Pediatric regimens for adult acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2009 Apr; 7(4):244-6.
    View in: PubMed
    Score: 0.011
  47. Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S231-8.
    View in: PubMed
    Score: 0.011
  48. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res. 2008 Nov 01; 14(21):7095-101.
    View in: PubMed
    Score: 0.011
  49. Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol. 2008 Jul; 15(4):400-7.
    View in: PubMed
    Score: 0.010
  50. Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2008 Jul; 6(7):487-8.
    View in: PubMed
    Score: 0.010
  51. Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008 Jul; 3(3):144-51.
    View in: PubMed
    Score: 0.010
  52. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54.
    View in: PubMed
    Score: 0.010
  53. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
    View in: PubMed
    Score: 0.010
  54. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.010
  55. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
    View in: PubMed
    Score: 0.010
  56. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006 May; 28(5):1099-103.
    View in: PubMed
    Score: 0.009
  57. Controversies in treatment of AML: case-based discussion. Hematology Am Soc Hematol Educ Program. 2006; 185-91.
    View in: PubMed
    Score: 0.009
  58. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.008
  59. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? Leukemia. 2005 Jan; 19(1):31-3.
    View in: PubMed
    Score: 0.008
  60. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
    View in: PubMed
    Score: 0.008
  61. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 10 22; 8(20):5297-5305.
    View in: PubMed
    Score: 0.008
  62. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446.
    View in: PubMed
    Score: 0.008
  63. Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia. Blood Adv. 2024 09 10; 8(17):4647-4650.
    View in: PubMed
    Score: 0.008
  64. Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3478-3490.
    View in: PubMed
    Score: 0.008
  65. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Adv. 2024 06 25; 8(12):3226-3236.
    View in: PubMed
    Score: 0.008
  66. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4.
    View in: PubMed
    Score: 0.008
  67. Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model. J Hematol Oncol. 2024 05 03; 17(1):28.
    View in: PubMed
    Score: 0.008
  68. Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nat Commun. 2024 May 01; 15(1):3681.
    View in: PubMed
    Score: 0.008
  69. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 04 23; 8(8):2020-2029.
    View in: PubMed
    Score: 0.008
  70. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024 04 18; 143(16):1616-1627.
    View in: PubMed
    Score: 0.008
  71. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell. 2024 Apr 08; 42(4):552-567.e6.
    View in: PubMed
    Score: 0.008
  72. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
    View in: PubMed
    Score: 0.008
  73. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 01 23; 8(2):429-440.
    View in: PubMed
    Score: 0.008
  74. Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL. JCO Oncol Pract. 2024 Apr; 20(4):491-502.
    View in: PubMed
    Score: 0.008
  75. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.008
  76. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
    View in: PubMed
    Score: 0.008
  77. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024 01; 38(1):45-57.
    View in: PubMed
    Score: 0.008
  78. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 Nov; 623(7989):1034-1043.
    View in: PubMed
    Score: 0.008
  79. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.
    View in: PubMed
    Score: 0.007
  80. Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017. Cancer. 2024 03 01; 130(5):750-769.
    View in: PubMed
    Score: 0.007
  81. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories. Blood Adv. 2023 10 24; 7(20):6048-6054.
    View in: PubMed
    Score: 0.007
  82. A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023 09 26; 7(18):5202-5209.
    View in: PubMed
    Score: 0.007
  83. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Adv. 2023 08 22; 7(16):4671-4675.
    View in: PubMed
    Score: 0.007
  84. Influence of participant and reviewer characteristics in application scores for a hematology research training program. Blood Adv. 2023 08 08; 7(15):4064-4071.
    View in: PubMed
    Score: 0.007
  85. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.007
  86. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363.
    View in: PubMed
    Score: 0.007
  87. Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Adv Sci (Weinh). 2023 08; 10(23):e2300445.
    View in: PubMed
    Score: 0.007
  88. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 08 01; 129(15):2308-2320.
    View in: PubMed
    Score: 0.007
  89. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023 06; 37(6):1194-1203.
    View in: PubMed
    Score: 0.007
  90. Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials. JCO Oncol Pract. 2023 06; 19(6):e877-e891.
    View in: PubMed
    Score: 0.007
  91. Minimal residual disease: current status in leukemia. Clin Adv Hematol Oncol. 2003 Apr; 1(4):210-1.
    View in: PubMed
    Score: 0.007
  92. Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970.
    View in: PubMed
    Score: 0.007
  93. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023 04; 37(4):788-798.
    View in: PubMed
    Score: 0.007
  94. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
    View in: PubMed
    Score: 0.007
  95. Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680.
    View in: PubMed
    Score: 0.007
  96. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023 01 24; 7(2):196-204.
    View in: PubMed
    Score: 0.007
  97. Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding. Expert Opin Drug Metab Toxicol. 2023 Jan-Jun; 19(6):357-366.
    View in: PubMed
    Score: 0.007
  98. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022 12 01; 107(12):2783-2793.
    View in: PubMed
    Score: 0.007
  99. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
    View in: PubMed
    Score: 0.007
  100. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
    View in: PubMed
    Score: 0.007
  101. D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia. Blood Adv. 2022 09 13; 6(17):5146-5151.
    View in: PubMed
    Score: 0.007
  102. Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents. J Assist Reprod Genet. 2022 Aug; 39(8):1733-1738.
    View in: PubMed
    Score: 0.007
  103. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022 06 16; 139(24):3519-3531.
    View in: PubMed
    Score: 0.007
  104. Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Adv. 2022 06 14; 6(11):3433-3439.
    View in: PubMed
    Score: 0.007
  105. Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Adv. 2022 06 14; 6(11):3386-3397.
    View in: PubMed
    Score: 0.007
  106. Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol. 2022 11 10; 40(32):3709-3718.
    View in: PubMed
    Score: 0.007
  107. Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat Cancer. 2022 06; 3(6):768-782.
    View in: PubMed
    Score: 0.007
  108. Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia. Biomed Pharmacother. 2022 Jun; 150:113000.
    View in: PubMed
    Score: 0.007
  109. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. Blood. 2022 04 07; 139(14):2212-2226.
    View in: PubMed
    Score: 0.007
  110. MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leuk Lymphoma. 2022 06; 63(6):1436-1444.
    View in: PubMed
    Score: 0.007
  111. SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 05 10; 40(14):1574-1582.
    View in: PubMed
    Score: 0.007
  112. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 11 23; 5(22):4691-4700.
    View in: PubMed
    Score: 0.007
  113. Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. Blood Rev. 2022 05; 53:100908.
    View in: PubMed
    Score: 0.007
  114. The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood. 2021 11 11; 138(19):1870-1884.
    View in: PubMed
    Score: 0.007
  115. Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv. 2021 11 09; 5(21):4352-4360.
    View in: PubMed
    Score: 0.007
  116. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nat Commun. 2021 10 29; 12(1):6233.
    View in: PubMed
    Score: 0.007
  117. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia. 2001 Sep; 15(9):1317-25.
    View in: PubMed
    Score: 0.006
  118. Self-reported positive impact of mentored clinical research training is associated with academic success in hematology. Blood Adv. 2021 07 27; 5(14):2919-2924.
    View in: PubMed
    Score: 0.006
  119. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Mol Cell. 2021 09 16; 81(18):3833-3847.e11.
    View in: PubMed
    Score: 0.006
  120. SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 11; 21(11):725-733.
    View in: PubMed
    Score: 0.006
  121. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787.
    View in: PubMed
    Score: 0.006
  122. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021 10 10; 39(29):3261-3272.
    View in: PubMed
    Score: 0.006
  123. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discov. 2021 11; 11(11):2846-2867.
    View in: PubMed
    Score: 0.006
  124. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 07; 35(7):2076-2085.
    View in: PubMed
    Score: 0.006
  125. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021 02 26; 12(1):1334.
    View in: PubMed
    Score: 0.006
  126. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.
    View in: PubMed
    Score: 0.006
  127. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma. 2021 07; 62(7):1765-1769.
    View in: PubMed
    Score: 0.006
  128. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021 03; 2(3):284-299.
    View in: PubMed
    Score: 0.006
  129. Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol. 2001 Jan; 13(1):14-20.
    View in: PubMed
    Score: 0.006
  130. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1289-305, viii-ix.
    View in: PubMed
    Score: 0.006
  131. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435.
    View in: PubMed
    Score: 0.006
  132. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858.
    View in: PubMed
    Score: 0.006
  133. Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists. Leuk Lymphoma. 2021 02; 62(2):387-398.
    View in: PubMed
    Score: 0.006
  134. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020 10 10; 10:CD013399.
    View in: PubMed
    Score: 0.006
  135. Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. Biol Blood Marrow Transplant. 2020 12; 26(12):2335-2345.
    View in: PubMed
    Score: 0.006
  136. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81.
    View in: PubMed
    Score: 0.006
  137. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81.
    View in: PubMed
    Score: 0.006
  138. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res. 2020 08; 95:106385.
    View in: PubMed
    Score: 0.006
  139. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.
    View in: PubMed
    Score: 0.006
  140. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma. 2020 08; 61(8):2012-2015.
    View in: PubMed
    Score: 0.006
  141. Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020 11; 55(11):2204-2206.
    View in: PubMed
    Score: 0.006
  142. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.006
  143. White blood cells 1: non-malignant disorders. Lancet. 2000 Apr 15; 355(9212):1351-7.
    View in: PubMed
    Score: 0.006
  144. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020 06; 95(6):583-593.
    View in: PubMed
    Score: 0.006
  145. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood. 2000 Apr 01; 95(7):2364-71.
    View in: PubMed
    Score: 0.006
  146. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020 03; 1(3):329-344.
    View in: PubMed
    Score: 0.006
  147. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.
    View in: PubMed
    Score: 0.006
  148. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020 02 25; 4(4):696-705.
    View in: PubMed
    Score: 0.006
  149. Impact of gender and caregiving responsibilities on academic success in hematology. Blood Adv. 2020 02 25; 4(4):755-761.
    View in: PubMed
    Score: 0.006
  150. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2020 03; 21(3):421-435.
    View in: PubMed
    Score: 0.006
  151. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020 02 11; 4(3):449-457.
    View in: PubMed
    Score: 0.006
  152. Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027.
    View in: PubMed
    Score: 0.006
  153. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168.
    View in: PubMed
    Score: 0.006
  154. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237.
    View in: PubMed
    Score: 0.006
  155. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.
    View in: PubMed
    Score: 0.006
  156. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.
    View in: PubMed
    Score: 0.006
  157. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020 03; 61(3):614-622.
    View in: PubMed
    Score: 0.006
  158. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097.
    View in: PubMed
    Score: 0.006
  159. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). J Geriatr Oncol. 2020 01; 11(1):107-113.
    View in: PubMed
    Score: 0.006
  160. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 11; 25(11):2113-2123.
    View in: PubMed
    Score: 0.006
  161. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
    View in: PubMed
    Score: 0.006
  162. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327.
    View in: PubMed
    Score: 0.005
  163. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2019 09; 25(9):1720-1729.
    View in: PubMed
    Score: 0.005
  164. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487.
    View in: PubMed
    Score: 0.005
  165. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
    View in: PubMed
    Score: 0.005
  166. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019 04; 94(4):408-416.
    View in: PubMed
    Score: 0.005
  167. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.
    View in: PubMed
    Score: 0.005
  168. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617.
    View in: PubMed
    Score: 0.005
  169. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019 03; 66(3):e27542.
    View in: PubMed
    Score: 0.005
  170. Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657.
    View in: PubMed
    Score: 0.005
  171. Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens. Am J Hematol. 2018 10; 93(10):1254-1266.
    View in: PubMed
    Score: 0.005
  172. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638.
    View in: PubMed
    Score: 0.005
  173. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):636-647.
    View in: PubMed
    Score: 0.005
  174. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. JAMA Oncol. 2018 05 01; 4(5):725-734.
    View in: PubMed
    Score: 0.005
  175. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303.
    View in: PubMed
    Score: 0.005
  176. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732.
    View in: PubMed
    Score: 0.005
  177. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456.
    View in: PubMed
    Score: 0.005
  178. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.
    View in: PubMed
    Score: 0.005
  179. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.005
  180. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018 01 15; 124(2):325-334.
    View in: PubMed
    Score: 0.005
  181. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365.
    View in: PubMed
    Score: 0.005
  182. De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest. 2017 09; 152(3):683-685.
    View in: PubMed
    Score: 0.005
  183. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 10; 18(10):1317-1326.
    View in: PubMed
    Score: 0.005
  184. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018 Jun; 24(4):299-308.
    View in: PubMed
    Score: 0.005
  185. Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma. Leukemia. 2017 06; 31(6):1450-1453.
    View in: PubMed
    Score: 0.005
  186. Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome. Cancer Epidemiol Biomarkers Prev. 2017 03; 26(3):312-320.
    View in: PubMed
    Score: 0.005
  187. Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 Jan; 15(1):26-36.
    View in: PubMed
    Score: 0.005
  188. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 11 24; 375(21):2023-2036.
    View in: PubMed
    Score: 0.005
  189. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol. 2017 Feb; 35(4):394-401.
    View in: PubMed
    Score: 0.005
  190. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017 04; 58(4):950-958.
    View in: PubMed
    Score: 0.005
  191. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016 11 08; 7:13331.
    View in: PubMed
    Score: 0.005
  192. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016 12; 48(12):1481-1489.
    View in: PubMed
    Score: 0.005
  193. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.
    View in: PubMed
    Score: 0.005
  194. Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer. 2017 Jan 01; 123(1):122-130.
    View in: PubMed
    Score: 0.005
  195. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39.
    View in: PubMed
    Score: 0.005
  196. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma. 2016 07; 57(7):1527-33.
    View in: PubMed
    Score: 0.004
  197. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53.
    View in: PubMed
    Score: 0.004
  198. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 08; 30(8):1672-81.
    View in: PubMed
    Score: 0.004
  199. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.
    View in: PubMed
    Score: 0.004
  200. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.004
  201. Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer. 2016 Mar 15; 122(6):954-61.
    View in: PubMed
    Score: 0.004
  202. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13.
    View in: PubMed
    Score: 0.004
  203. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
    View in: PubMed
    Score: 0.004
  204. Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leuk Res. 2015 Dec; 39(12):1437-42.
    View in: PubMed
    Score: 0.004
  205. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015 Sep 25; 5:e350.
    View in: PubMed
    Score: 0.004
  206. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110.
    View in: PubMed
    Score: 0.004
  207. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):694-8.
    View in: PubMed
    Score: 0.004
  208. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34.
    View in: PubMed
    Score: 0.004
  209. Minimal residual disease in acute myeloid leukemia--current status and future perspectives. Curr Hematol Malig Rep. 2015 Jun; 10(2):132-44.
    View in: PubMed
    Score: 0.004
  210. Inclusion of Adolescents and Young Adults in Cancer Clinical Trials. Semin Oncol Nurs. 2015 Aug; 31(3):197-205.
    View in: PubMed
    Score: 0.004
  211. Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia. 2015 Oct; 29(10):2113-6.
    View in: PubMed
    Score: 0.004
  212. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget. 2014 Dec 15; 5(23):12371-82.
    View in: PubMed
    Score: 0.004
  213. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015 Jan 22; 125(4):680-6.
    View in: PubMed
    Score: 0.004
  214. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.
    View in: PubMed
    Score: 0.004
  215. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. Leukemia. 1994 Nov; 8(11):1918-22.
    View in: PubMed
    Score: 0.004
  216. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11; 371(11):1005-15.
    View in: PubMed
    Score: 0.004
  217. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73.
    View in: PubMed
    Score: 0.004
  218. Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. Leuk Res. 2014 Sep; 38(9):1091-6.
    View in: PubMed
    Score: 0.004
  219. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9.
    View in: PubMed
    Score: 0.004
  220. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014 May 12; 25(5):652-65.
    View in: PubMed
    Score: 0.004
  221. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014 May; 165(4):497-503.
    View in: PubMed
    Score: 0.004
  222. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014 Jul; 55(7):1523-32.
    View in: PubMed
    Score: 0.004
  223. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.
    View in: PubMed
    Score: 0.004
  224. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014 Apr 01; 120(7):1010-7.
    View in: PubMed
    Score: 0.004
  225. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32.
    View in: PubMed
    Score: 0.004
  226. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
    View in: PubMed
    Score: 0.004
  227. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014 Jan; 99(1):111-5.
    View in: PubMed
    Score: 0.004
  228. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9.
    View in: PubMed
    Score: 0.004
  229. Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies. Curr Opin Hematol. 2013 Mar; 20(2):115-22.
    View in: PubMed
    Score: 0.004
  230. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013 Mar; 45(3):242-52.
    View in: PubMed
    Score: 0.004
  231. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20; 31(6):676-83.
    View in: PubMed
    Score: 0.004
  232. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013 May; 19(5):682-91.
    View in: PubMed
    Score: 0.003
  233. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104.
    View in: PubMed
    Score: 0.003
  234. Children, adolescents, and young adults with leukemia: the empty half of the glass is growing. J Clin Oncol. 2012 Nov 10; 30(32):4037-8; author reply 4038-9.
    View in: PubMed
    Score: 0.003
  235. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905.
    View in: PubMed
    Score: 0.003
  236. Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012 Sep 06; 120(10):2098-108.
    View in: PubMed
    Score: 0.003
  237. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15.
    View in: PubMed
    Score: 0.003
  238. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7.
    View in: PubMed
    Score: 0.003
  239. Characterization of yeast artificial chromosomes containing interleukin genes on human chromosome 5. Cytogenet Cell Genet. 1992; 61(4):263-5.
    View in: PubMed
    Score: 0.003
  240. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
    View in: PubMed
    Score: 0.003
  241. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45.
    View in: PubMed
    Score: 0.003
  242. Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor. Ann Oncol. 1991 Jul; 2(7):522-3.
    View in: PubMed
    Score: 0.003
  243. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun; 30(3):1107-15.
    View in: PubMed
    Score: 0.003
  244. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
    View in: PubMed
    Score: 0.003
  245. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.
    View in: PubMed
    Score: 0.003
  246. Ultrasonic endoluminal examination in the follow-up of colorectal cancer. Initial experience and results. Int J Colorectal Dis. 1990 Dec; 5(4):188-94.
    View in: PubMed
    Score: 0.003
  247. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
    View in: PubMed
    Score: 0.003
  248. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11; 116(19):3751-7.
    View in: PubMed
    Score: 0.003
  249. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33.
    View in: PubMed
    Score: 0.003
  250. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46.
    View in: PubMed
    Score: 0.003
  251. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211.
    View in: PubMed
    Score: 0.003
  252. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.
    View in: PubMed
    Score: 0.003
  253. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
    View in: PubMed
    Score: 0.003
  254. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010 Mar 01; 116(5):1165-76.
    View in: PubMed
    Score: 0.003
  255. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 2009 Dec 01; 115(23):5490-8.
    View in: PubMed
    Score: 0.003
  256. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec; 50(12):1958-63.
    View in: PubMed
    Score: 0.003
  257. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8.
    View in: PubMed
    Score: 0.003
  258. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
    View in: PubMed
    Score: 0.003
  259. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 05; 114(19):4027-33.
    View in: PubMed
    Score: 0.003
  260. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1.
    View in: PubMed
    Score: 0.003
  261. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009 Aug 27; 114(9):1736-45.
    View in: PubMed
    Score: 0.003
  262. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.003
  263. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
    View in: PubMed
    Score: 0.003
  264. Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant. 2008 Aug; 14(8):938-41.
    View in: PubMed
    Score: 0.003
  265. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64.
    View in: PubMed
    Score: 0.003
  266. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008 May 01; 14(9):2756-62.
    View in: PubMed
    Score: 0.003
  267. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008 Apr 15; 14(8):2444-9.
    View in: PubMed
    Score: 0.003
  268. The concept of happiness: a multidimensional scaling investigation. Int J Aging Hum Dev. 1988; 27(2):141-54.
    View in: PubMed
    Score: 0.002
  269. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
    View in: PubMed
    Score: 0.002
  270. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805.
    View in: PubMed
    Score: 0.002
  271. Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant. 2007 Jul; 40(2):181.
    View in: PubMed
    Score: 0.002
  272. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.
    View in: PubMed
    Score: 0.002
  273. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006 Jul; 30(7):777-83.
    View in: PubMed
    Score: 0.002
  274. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006 Jul 01; 108(1):28-37.
    View in: PubMed
    Score: 0.002
  275. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006 Feb 21; 103(8):2794-9.
    View in: PubMed
    Score: 0.002
  276. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10.
    View in: PubMed
    Score: 0.002
  277. [Results of the surgical treatment of gallbladder carcinomas]. Chirurg. 1985 Jul; 56(7):440-4.
    View in: PubMed
    Score: 0.002
  278. Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J Hematol. 2005 Jun; 79(2):119-27.
    View in: PubMed
    Score: 0.002
  279. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005 May; 35(10):965-70.
    View in: PubMed
    Score: 0.002
  280. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol. 2005 May 20; 23(15):3404-11.
    View in: PubMed
    Score: 0.002
  281. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
    View in: PubMed
    Score: 0.002
  282. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004 Jun; 10(6):386-94.
    View in: PubMed
    Score: 0.002
  283. G3139, a BCL-2 antisense oligo-nucleotide, in AML. Ann Hematol. 2004; 83 Suppl 1:S93-4.
    View in: PubMed
    Score: 0.002
  284. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6.
    View in: PubMed
    Score: 0.002
  285. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13.
    View in: PubMed
    Score: 0.002
  286. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant. 2003 May; 31(9):813-6.
    View in: PubMed
    Score: 0.002
  287. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymphoma. 2003 Jan; 44(1):39-48.
    View in: PubMed
    Score: 0.002
  288. Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. Leukemia. 2002 Nov; 16(11):2275-84.
    View in: PubMed
    Score: 0.002
  289. Actinomycosis presenting as an oral ulcer in a neutropenic patient. South Med J. 2002 Sep; 95(9):1105.
    View in: PubMed
    Score: 0.002
  290. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002 Mar 15; 99(6):2255-8.
    View in: PubMed
    Score: 0.002
  291. [Rational EDP-basic documentation in the surgical clinic]. Chirurg. 1982 Mar; 53(3):176-83.
    View in: PubMed
    Score: 0.002
  292. Progressive transformation of germinal centers. Report of 2 cases and review of the literature. Acta Haematol. 2002; 108(1):33-8.
    View in: PubMed
    Score: 0.002
  293. Stem cell transplantation eliminates alloantibody in a highly sensitized patient. Transplantation. 2001 Nov 27; 72(10):1653-5.
    View in: PubMed
    Score: 0.002
  294. [Reimplantation of peripheral parts of the extremities. 808 cases and functional results]. Minerva Chir. 1981 Oct 31; 36(20):1337-44.
    View in: PubMed
    Score: 0.002
  295. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant. 2001 Sep; 28(6):557-62.
    View in: PubMed
    Score: 0.002
  296. Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res. 2001 Mar 01; 61(5):2307-10.
    View in: PubMed
    Score: 0.002
  297. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol. 2001 Feb 01; 19(3):634-44.
    View in: PubMed
    Score: 0.002
  298. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000 Aug; 26(4):445-9.
    View in: PubMed
    Score: 0.001
  299. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest. 2000 Jul; 106(1):117-24.
    View in: PubMed
    Score: 0.001
  300. CD5+ immunophenotype in the bone marrow but not in the peripheral blood in a patient with hairy cell leukemia. Acta Haematol. 2000; 103(4):210-3.
    View in: PubMed
    Score: 0.001
  301. Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol. 1999 Jul; 27(7):1124-32.
    View in: PubMed
    Score: 0.001
  302. A phase II trial of interleukin-2 in myelodysplastic syndromes. Br J Haematol. 1998 Apr; 101(1):205-7.
    View in: PubMed
    Score: 0.001
  303. [Prognostic factors in perforating diverticulitis of the large intestine]. Chirurg. 1998 Apr; 69(4):443-9.
    View in: PubMed
    Score: 0.001
  304. [Characteristics of normal cross-sectional anatomy of the skin in high resolution magnetic resonance tomography]. Hautarzt. 1997 Jan; 48(1):26-30.
    View in: PubMed
    Score: 0.001
  305. [Value of individually risk-adjusted after-care--economic management of oncologic effectiveness?]. Langenbecks Arch Chir Suppl Kongressbd. 1997; 114:665-8.
    View in: PubMed
    Score: 0.001
  306. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 1996 Oct 01; 88(7):2665-70.
    View in: PubMed
    Score: 0.001
  307. [Psychological stress on patients in tumor after-care after R0 resection of colorectal carcinomas]. Chirurg. 1996 Jun; 67(6):604-9; discussion 609-10.
    View in: PubMed
    Score: 0.001
  308. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996 May; 52(1):42-6.
    View in: PubMed
    Score: 0.001
  309. [Surgical treatment of diverticulitis of the large intestine--a plea for early elective resection]. Zentralbl Chir. 1996; 121(3):190-200.
    View in: PubMed
    Score: 0.001
  310. [Surgical therapy of sigmoid diverticulitis in elderly patients.--What decides against early elective resection]. Langenbecks Arch Chir Suppl Kongressbd. 1996; 113:470-3.
    View in: PubMed
    Score: 0.001
  311. [Acceptance and effectiveness of surgical vascular consultation--is it worthwhile?]. Chirurg. 1995 Dec; 66(12):1239-44; discussion 1245-6.
    View in: PubMed
    Score: 0.001
  312. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Bone Marrow Transplant. 1995 Nov; 16(5):655-61.
    View in: PubMed
    Score: 0.001
  313. [Long-term outcome of the donor site after free, microvascular pedicled iliac crest transplantation: experiences with 95 cases]. Handchir Mikrochir Plast Chir. 1995 Sep; 27(5):233-41.
    View in: PubMed
    Score: 0.001
  314. [Is the surgeon a prognostically relevant factor after R0-resection of colorectal carcinoma?]. Chirurg. 1995 Apr; 66(4):334-42; discussion 342-3.
    View in: PubMed
    Score: 0.001
  315. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia. 1995 Mar; 9(3):433-9.
    View in: PubMed
    Score: 0.001
  316. [Risk analysis of primary endoprosthetic management of proximal femur fractures]. Unfallchirurgie. 1994 Aug; 20(4):216-22.
    View in: PubMed
    Score: 0.001
  317. CGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the Philadelphia chromosome. Genes Chromosomes Cancer. 1994 Feb; 9(2):141-4.
    View in: PubMed
    Score: 0.001
  318. [Results of management of pertrochanteric comminuted fractures in the elderly with a tumor shaft endoprostheses]. Aktuelle Traumatol. 1994 Feb; 24(1):6-11.
    View in: PubMed
    Score: 0.001
  319. [Results of regular follow-up after removal of colorectal adenomas]. Med Klin (Munich). 1993 Aug 15; 88(8):471-7.
    View in: PubMed
    Score: 0.001
  320. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993 Jun 15; 90(12):5484-8.
    View in: PubMed
    Score: 0.001
  321. Listeriosis after 2-chlorodeoxyadenosine treatment. N Engl J Med. 1993 Mar 18; 328(11):813-4.
    View in: PubMed
    Score: 0.001
  322. Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma? Dis Colon Rectum. 1993 Mar; 36(3):280-6.
    View in: PubMed
    Score: 0.001
  323. [Preoperative esophagogastroduodenoscopy before elective surgical therapy of symptomatic cholelithiasis]. Leber Magen Darm. 1992 Nov; 22(6):225-9.
    View in: PubMed
    Score: 0.001
  324. [Preoperative hemodilution before elective resections of colorectal cancers for sparing homologous blood transfusion]. Leber Magen Darm. 1992 May; 22(3):111-5.
    View in: PubMed
    Score: 0.001
  325. [Postoperative complications of elective resection of the colon in diverticulitis]. Dtsch Med Wochenschr. 1992 Jan 10; 117(2):41-5.
    View in: PubMed
    Score: 0.001
  326. [Inguinal hernia repair modified by Kirschner. A critical analysis after 11 years of clinical experience]. Langenbecks Arch Chir. 1992; 377(6):324-31.
    View in: PubMed
    Score: 0.001
  327. CD5+, CD11c+, CD20+ hairy cell leukemia. Blood. 1991 Apr 01; 77(7):1617-9.
    View in: PubMed
    Score: 0.001
  328. [Follow-up in stomach carcinoma]. Leber Magen Darm. 1991 Mar; 21(2):68, 71-4.
    View in: PubMed
    Score: 0.001
  329. [Individual risk-related after-care in colorectal cancer?]. Langenbecks Arch Chir. 1991; 376(6):314-22.
    View in: PubMed
    Score: 0.001
  330. [Morbidity and mortality after elective resections of colorectal cancers]. Langenbecks Arch Chir. 1991; 376(2):93-101.
    View in: PubMed
    Score: 0.001
  331. [The effect of age and sex on localization, tumor stage and prognosis of colorectal carcinoma]. Med Klin (Munich). 1990 Oct 15; 85(10):586-90.
    View in: PubMed
    Score: 0.001
  332. [Surgical treatment of large thoracic wall recurrences in breast cancer]. Chirurg. 1987 Sep; 58(9):607-11.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.